- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01942746
Blueberry Effects on Dark Vision and Glare Recovery
September 11, 2013 updated by: Wilhelmina Kalt, Atlantic Food and Horticulture Research Center
Placebo-controlled Cross-over Studies Examining Blueberries Effects on Dark Vision and Recovery After Photo-bleaching
Clinical evidence for effects of plant anthocyanins on vision, and particularly night vision is controversial.
Two clinical trials were conducted to investigate whether blueberry juice consumption affected visual dark adaptation, functional night vision, and recovery after photo-bleaching of the retina.
One trial (S2) employed a 3 week intervention and washout period, and two doses of blueberries plus a placebo.
The other trial (L1) employed a 12 week intervention plus an 8 week washout and tested one blueberry juice dose against a juice placebo.
Study Overview
Status
Completed
Conditions
Detailed Description
Vision Tests: 1. Dark adaptometry, 2. scotopic visual acuity, 3. scotopic contrast sensitivity, 4. rod/cone conversion, 5. recovery after retinal photobleaching
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canada, B4N1J5
- Atlantic Food and Horicultural Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
33 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- visual acuity better than 6/7.5 on EDTRS acuity chart at 2.5m
- visual contrast sensitivity within normal range at 2.5m as tested on Visteck 3000
- stereo acuity better than 80 seconds of arc on Frisby stereoacuity test
- no ocular history other than refractive glasses
- no family history of eye disease
Exclusion Criteria:
- family history of retinal degeneration, glaucoma, diabetes, hypertension, cataract, or amblyopia (dimness in vision).
- evidence in subject (upon examination) of amblyopia (dimness in vision), manifest strabismus (unable to focus both eyes on one spot), or anisotropia (non-uniform responsiveness between both eyes).
- intraocular pressure above 21mmHG from an average of three measures using Mentor tonopen-XL
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Blueberry Juice
Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue').
Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
|
Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars.
Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20)
mg anthocyanins (C3G) eq/g dry mass.
Other Names:
Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars.
Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20)
mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09)
mg C3GE/g dry mass after 3 months refrigerated storage.
Other Names:
|
Active Comparator: Blueberry Capsules
Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2).
Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
|
Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules.
Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18)
mg C3G eq per capsule.
Other Names:
|
Placebo Comparator: Placebo
Volunteers consumed in S2 three placebo capsules daily for 3 weeks.
In L1 volunteers consumed 300ml placebo juice for twelve weeks.
Placebo products contained no anthocyanins.
|
Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules.
Red beets do not contain anthocyanins.
Other Names:
Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized.
The placebo juice contains no anthocyanins.
|
No Intervention: Washout (S2 and L1)
Washout periods involved no study products.
Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of vision adaptation to low light after blueberry juice and placebo ingestion for 3 weeks (S2).
Time Frame: Pre-intervention, and changes after 3 weeks of intervention, and again after 3 weeks of washout
|
Effect of blueberry products and placebo on the rate of vision adaptation to low light.
The rate of vision adaptation is measured by lowest perceptible light intensity after 30 min of darkness (dark threshold); time to reach dark threshold (min); time to reach rod/cone transition (min) [Time Frame: Pre-intervention, after 3 weeks intervention, again after a 3 week washout.]
[Designated as safety issue: No]
|
Pre-intervention, and changes after 3 weeks of intervention, and again after 3 weeks of washout
|
Rate of vision adaptation to low light after ingestion of blueberry juice and placebo for 12 weeks (L1).
Time Frame: Preintervention, and changes after 8 and 12 weeks of intervention and after 4 and 8 weeks of washout
|
Effect of blueberry products and placebo on the rate of vision adaptation to low light.
The rate of vision adaptation is measured by lowest perceptible light intensity after 30 min of darkness (dark threshold); time to reach dark threshold (min); time to reach rod/cone transition (min) [Time Frame: Pre-intervention, after 8 and 12 weeks intervention, and again after 4 and 8 weeks washout] [Designated as safety issue: No]
|
Preintervention, and changes after 8 and 12 weeks of intervention and after 4 and 8 weeks of washout
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of recovery of visual acuity after retinal photostress (S2).
Time Frame: Pre-intervention testing and testing for changes after 3 weeks of intervention and 3 weeks of washout
|
After dark adaptation testing (primary outcome) and contrast sensitivity and visual acuity testing (other pre-specified outcome measures), participants are subjected to photostress of the retina using bright light.
The time (sec) required to recover pre-stress acuity is measured.
|
Pre-intervention testing and testing for changes after 3 weeks of intervention and 3 weeks of washout
|
Rate of recovery of visual acquity after retinal photostress (L1).
Time Frame: Pre-intervention and then testing for changes after 8 and 12 weeks of intervention and 4 and 8 weeks of washout.
|
After dark adaptation testing (primary outcome) and contrast sensitivity and visual acuity testing (other pre-specified outcome measures) participants are subjected to photostress of the retina using bright light.
The time (sec) required to recover pre-stress acuity is measured.
|
Pre-intervention and then testing for changes after 8 and 12 weeks of intervention and 4 and 8 weeks of washout.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual acuity and contrast sensitivity testing after dark adaptation (S2).
Time Frame: Testing preintervention and testing for changes after 3 weeks of intervention and 3 weeks of washout
|
After dark adaptation testing (primary outcome measure) and before measuring rate of recovery from photo stress (secondary outcome) visual acuity in darkness and contrast sensitivity in darkness was measured using defined optotypes with different degrees of crowding and contrast.
Performance was defined as the number of correct answers in 12 tests of acuity and 8 tests of contrast sensitivity.
|
Testing preintervention and testing for changes after 3 weeks of intervention and 3 weeks of washout
|
Visual acuity and contrast sensitivity testing after dark adaptation (L1).
Time Frame: Testing preintervention and testing for changes after 8 & 12 weeks of intervention and 4 & 8 weeks of washout
|
After dark adaptation testing (primary outcome measure) and before testing rate of recovery from photo stress (secondary outcome) visual acuity in darkness and contrast sensitivity in darkness was measured using defined optotypes with different degrees of crowding and contrast.
Performance was defined as the number of correct answers in 12 tests of acuity and 8 tests of contrast sensitivity.
|
Testing preintervention and testing for changes after 8 & 12 weeks of intervention and 4 & 8 weeks of washout
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Wilhelmina Kalt, PhD, Agriculture and Agri-Food Canada
- Principal Investigator: Francois Tremblay, PhD, Dalhousie University and IWK Health Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2005
Primary Completion (Actual)
July 1, 2006
Study Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
May 23, 2013
First Submitted That Met QC Criteria
September 11, 2013
First Posted (Estimate)
September 16, 2013
Study Record Updates
Last Update Posted (Estimate)
September 16, 2013
Last Update Submitted That Met QC Criteria
September 11, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Blueberries and Vision
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blindness and Low Vision
-
Vortant Technologies, LLCSuspendedBlindness and Low VisionUnited States
-
Lawson Health Research InstituteUnknownLow Vision Aids | Low Vision, One Eye, Unspecified Eye | Low Vision BlindnessCanada
-
Second Sight Medical ProductsBoston Biomedical AssociatesSuspendedBlindness, AcquiredUnited States
-
Saglik Bilimleri UniversitesiCompletedBlindness | Young Adult | Blindness Congenital | Blindness and Low Vision | Visual DisorderTurkey
-
Istituti Clinici Scientifici Maugeri SpAActive, not recruiting
-
Smith-Kettlewell Eye Research InstituteRecruitingBlindness | Low Vision | Blindness, Acquired | Blindness, CompleteUnited States
-
State University of New York College of OptometryState University of New York College of OptometryRecruitingQuality of Life | Visual Impairment | Functional Visual Loss | Low Vision BlindnessUnited States
-
University of DelawareRecruiting
-
Józef Piłsudski University of Physical EducationCompletedBlindness | Visual ImpairmentPoland
-
Istituto Italiano di TecnologiaNot yet recruitingBlindness | Visual Impairment
Clinical Trials on Blueberry Juice S2
-
University of Prince Edward IslandCompleted
-
University of CincinnatiU.S. Highbush Blueberry Council; Welch Foods IncorporatedCompleted
-
Atlantic Food and Horticulture Research CenterCompleted
-
University of OsloUllevaal University HospitalCompletedCardiovascular Disease
-
Purdue UniversityUnknownOsteoporosis, Postmenopausal | Bone Loss, Age-relatedUnited States
-
Duke UniversityU.S. Highbush Blueberry CouncilCompletedSedentary Lifestyle | Blood Pressure | Overweight and Obesity | Arterial StiffnessUnited States
-
University of Mississippi Medical CenterU.S. Highbush Blueberry CouncilCompleted
-
University of ReadingNaurex, Inc, an affiliate of Allergan plcCompletedCognitive DeclineUnited Kingdom
-
Appalachian State UniversityNorth Carolina State University; SinnovaTekCompleted
-
Northumbria UniversityCompletedCognitive Change | Blood Pressure | Vascular StiffnessUnited Kingdom